PRESS RELEASE

Shortcuts 2021 2020 2019 2018 2017 2016 2015

2021

• Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia’s Board of Directors

2020

• BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies

• BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed

• BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The Market Under NASDAQ Rules

• BioCardia Anticipates DSMB Feedback on Interim Data from Pivotal Phase 3 CardiAMP Heart Failure Trial

• BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

• BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used In CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems

• BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights

• Published Peer-Reviewed Initial Data From BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function

• BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery

• BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

• BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights

• BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020

• BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia

• BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era

• BioCardia Announces Pricing of $10.0 Million Public Offering

• BioCardia Reports First Quarter 2020 Financial Results and Business Highlights

• BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure

• BioCardia Announces FDA-Recommended Modifications to Primary Endpoint for CardiAMP Cell Therapy Heart Failure Trial to Support Marketing Approval

• BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart

• BioCardia Announces Litigation Financing in the Case Captioned Boston Scientific Corp., et al., v. BioCardia, Inc.

• BioCardia Reports 2019 Financial Results and Recent Business Highlights

• BioCardia Announces Positive DSMB Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study, As Planned

• BioCardia Announces Timing For Prespecified Data Safety Monitoring Board Report on Pivotal CardiAMP Heart Failure Trial

• BioCardia Announces FDA Clearance of Morph DNA Deflectable Guide Catheter

• BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery

2019

• BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights

• BioCardia to Present at Dawson James Securities' 5th Annual Small Cap Growth Conference

• BioCardia Receives CE Mark Renewal for Helix Biotherapeutic Delivery Catheter and Morph Guide Catheter Through May 2024

• BioCardia Announces the Appointment of Two New Board Members

• BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures

• BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned

• BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights

• BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery

• BioCardia Announces Closing of $10.0 Million Public Offering

• BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to NASDAQ

• BioCardia Signs Exclusive Development Agreement with AstraZeneca

• BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery

• BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange

• Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia's Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class

• Biocardia Reports 2019 First Quarter Financial Results and Business Highlights

• BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transeptal Access to Heart

• BioCardia Reports 2018 Financial Results and Recent Business Highlights

2018

• BioCardia Submits 510(K) Application To FDA For AVANCE Steerable Introducer For Transseptal Access To Heart

• Positive 12-Month Data on BioCardia's Investigational CardiAMP Cell Therapy System for Heart Failure Presented at American Heart Association Scientific Sessions 2018

• BioCardia Reports Third Quarter 2018 Financial Results and Business Highlights

• BioCardia Welcomes Cardiovascular Device Veteran Mark Schwartz as Vice President of Clinical Affairs

• BioCardia and CellProThera Partner for Clinical Trial and Marketing in Singapore of Early Stem Cell Therapy for Patients Following Myocardial Infarction

• Positive Data on BioCardia's Investigational CardiAMP Cell Therapy for Heart Failure Presented at Transcatheter Cardiovascular Therapeutics (TCT) Conference

• BioCardia Receives Two New U.S. Patents - Patents Cover Methods of Preparing Mesenchymal Stem Cell Therapy to Treat Heart Failure and Transradial Delivery of Biotherapeutic Agents to the Heart

• Preliminary Results From BioCardia's Phase III Pivotal CardiAMP Heart Failure Trial Reported in Circulation Research Journal

• BioCardia, Inc. Reports Second Quarter 2018 Financial Results and Business Highlights

• BioCardia, Inc. Reports First Quarter 2018 Financial Results and Business Highlights

• Centers for Medicare and Medicaid Services Approves Reimbursement for BioCardia’s CardiAMP Cell Therapy in Pivotal Clinical Trial Studying Second Indication in Chronic Myocardial Ischemia

• BioCardia Receives New Potency Assay Patent, Providing Further Protection to Autologous Cell Therapy Programs in Heart Failure and Refractory Angina

• BioCardia Presents at Alliance for Regenerative Medicine’s (ARM’s) Annual Cell & Gene Therapy Investor Day

• Phase III CardiAMP Heart Failure Trial Featured in American Heart Journal

• BioCardia, Inc. Reports Fourth Quarter 2017 Financial Results and Business Highlights

• CardiAMP Cell Therapy Receives FDA Approval for Pivotal Trial in Chronic Myocardial Ischemia

• BioCardia Submits Clinical Trial to FDA for New Indication of Chronic Myocardial Ischemia for CardiAMP Cell Therapy

2017

• BioCardia, Inc. Reports Third Quarter 2017 Financial Results and Business Highlights

• Dr. Ian McNiece Appointed Biocardia Chief Scientific Officer

• Biocardia Announces Revised Effective Date of One-for-Twelve Reverse Stock Split

• Biocardia Announces Reverse Stock Split and Release of Indemnity Holdback Shares

• Biocardia Receives U.S. Patent Covering Morph Product Family Design

• Biocardia Announces Successful Interim Safety Analysis in its Phase 3 Clinical Trial of Cardiamp Stem Cell Therapy for Heart Failure

• BioCardia Announces Publication of 12-Month Results from Phase II TRIDENT Clinical Trial That Shows Positive Safety Profile for Allogeneic Bone Marrow Stem Cells Delivered with Helix Transendocardial Delivery System

• BioCardia’s CardiAMP Heart Failure Trial Design to be Presented at Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine

• BioCardia receives US Patent covering a method of preparing and characterizing mesenchymal cells, providing further protection to CardiALLO cell therapy program

• BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial

• Study Shows Helix Transendocardial Delivery System Enables Greater Myocardial Retention of Stem Cell Therapy

• BioCardia to Present at the 5th Annual Cell & Gene Investor Day

• Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with CardiAMP Cell Therapy for Ischemic Heart Failure in Phase III Clinical Trial

• BioCardia to Present at the 9th Annual Biotech Showcase in San Francisco

2016

• CardiAMP Pivotal Heart Failure Trial Initiated at Two US Centers

• BioCardia receives another US Patent covering a method of treating heart attack tissue damage with a patient’s own progenitor cells, providing further protection to Phase III CardiAMP program

• BioCardia receives US Patent covering a method of treating heart attack tissue damage with a patient’s own progenitor cells, providing further protection to Phase III CardiAMP program

• BioCardia Chairman of the Board Letter to Shareholders

• BioCardia Closes Merger with Tiger X Medical, Inc.

• BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP® Cell Therapy System for the Treatment of Heart Failure

• BioCardia® receives award from the Maryland Stem Cell Research Fund for CardiAMP cell therapy program for the treatment of ischemic heart failure

• BioCardia® Receives US Patent Covering a Method of Producing Mesenchymal Stem Cells Using a Single Patient Donor for Both Source Cells and Culture Medium

• BioCardia®, Inc. Announces Two Presentations Related to Cardiamp Cell Therapy at Cardiovascular Research Technologies in Washington DC

• BioCardia Announces Upcoming Cell Therapy Presentations at Cardiovascular Research Technologies Conference

2015

• BioCardia to Present at 2015 Stem Cell Meeting on the Mesa

• BioCardia, Inc. Files Registration Statement for Proposed Initial Public Offering